As of June 14, 2026, high-fidelity 3D-bioprinted tumor models have established a new clinical standard for ex vivo drug screening in rare sarcomas. By bioprinting patient-derived cancer cells along with stromal cells and blood vessels, researchers can construct model tissues that replicate the physical structure and drug resistance profiles of the patient's actual tumor.

At Onco Medicine, we recognize the vital role that ex vivo functional testing plays in selecting cancer therapies. Sourcing and supplying standard-of-care and novel drug candidates for patient-specific model screening help clinical teams identify the most effective treatments before administering them to the patient.

How 3D Bioprinting Improves Oncology Care

• Replicating the Microenvironment: Bioprinted models incorporate extracellular matrix, immune cells, and vascular channels, mimicking the drug barriers found in solid tumors.
• High-Throughput Testing: Automated platforms can test dozens of combination therapies against multiple bioprinted copies of a patient's tumor simultaneously.
• Sparing Patient Toxicity: Testing toxicity and efficacy on the bioprinted model first ensures patients avoid ineffective chemo courses.

Science-driven oncology starts with personalized biological evidence. Replicating tumor biology outside the body is a powerful therapeutic avenue. Onco Medicine is proud to support the clinical networks bringing these next-generation diagnostic tools to the forefront of patient care.